Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.

Mosrati MA, Willander K, Falk IJ, Hermanson M, Höglund M, Stockelberg D, Wei Y, Lotfi K, Söderkvist P.

Oncotarget. 2015 Sep 22;6(28):25109-20. doi: 10.18632/oncotarget.4668.

2.

Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia.

Willander K, Falk IJ, Chaireti R, Paul E, Hermansson M, Gréen H, Lotfi K, Söderkvist P.

Biomark Res. 2014 Oct 8;2:18. doi: 10.1186/2050-7771-2-18. eCollection 2014.

3.

TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.

Falk IJ, Willander K, Chaireti R, Lund J, Nahi H, Hermanson M, Gréen H, Lotfi K, Söderkvist P.

Eur J Haematol. 2015 Apr;94(4):355-62. doi: 10.1111/ejh.12438. Epub 2014 Oct 1.

4.

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nückel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm M, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, Greil R, Döhner H, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC).

Haematologica. 2014 Aug;99(8):1285-91. doi: 10.3324/haematol.2013.101170.

5.

NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients.

Willander K, Dutta RK, Ungerbäck J, Gunnarsson R, Juliusson G, Fredrikson M, Linderholm M, Söderkvist P.

BMC Cancer. 2013 Jun 4;13:274. doi: 10.1186/1471-2407-13-274.

6.

MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.

Willander K, Ungerbäck J, Karlsson K, Fredrikson M, Söderkvist P, Linderholm M.

Eur J Haematol. 2010 Sep;85(3):251-6. doi: 10.1111/j.1600-0609.2010.01470.x. Epub 2010 May 14.

PMID:
20491880
7.

A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies.

Lanemo Myhrinder A, Hellqvist E, Sidorova E, Söderberg A, Baxendale H, Dahle C, Willander K, Tobin G, Bäckman E, Söderberg O, Rosenquist R, Hörkkö S, Rosén A.

Blood. 2008 Apr 1;111(7):3838-48. doi: 10.1182/blood-2007-11-125450. Epub 2008 Jan 25.

PMID:
18223168
8.

Absence of hot spot mutations of the PIK3CA gene in acute myeloid leukaemia.

Hummerdal P, Andersson P, Willander K, Linderholm M, Söderkvist P, Jönsson JI.

Eur J Haematol. 2006 Jul;77(1):86-7. Epub 2006 Mar 27. No abstract available.

PMID:
16573740
9.

Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome.

Tobin G, Thunberg U, Laurell A, Karlsson K, Aleskog A, Willander K, Söderberg O, Merup M, Vilpo J, Hultdin M, Sundström C, Roos G, Rosenquist R.

Haematologica. 2005 Apr;90(4):465-9.

10.

Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia.

Tobin G, Thunberg U, Karlsson K, Murray F, Laurell A, Willander K, Enblad G, Merup M, Vilpo J, Juliusson G, Sundström C, Söderberg O, Roos G, Rosenquist R.

Blood. 2004 Nov 1;104(9):2879-85. Epub 2004 Jun 24.

PMID:
15217826
11.

Production of transforming growth factor alpha by human leukemia cells (HL-60 and U-937) during monocytic differentiation.

Walz TM, Malm C, Nishikawa BK, Willander K, Wingren S, Wasteson A.

Leukemia. 1995 Apr;9(4):671-6.

PMID:
7536865

Supplemental Content

Loading ...
Support Center